Venus Remedies share news, announcements and annual reports
NSE: VENUSREMBSE: 526953Pharmaceuticals & BiotechnologySmall Cap
Venus Remedies Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed May 1995 on BSE, Dec 2006 on NSE
Last close ₹1,238.60down ₹50.70 (3.93%)BSE ₹1,231.75
Share price at the NSE close on 30 Oct 2026. Previous close ₹1,289.30.
30 Oct: open ₹1,290.00, high ₹1,319.00, low ₹1,225.10
52-week range of traded prices to 30 Oct 2026
₹432.10Low, 31 Oct 2025₹2,044.30High, 29 Jun 2026
- Under NSE's long-term additional surveillance, stage IV, on the list for 30 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Delivery only: shares bought must be paid for in full, with no selling on the same day.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹1,656 Cr1,337th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 13.61
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.35
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.81%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 18.7%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 21.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day. Volume in the glossary
- 48,127
Venus Remedies board and management
24 filed, newest first.
Aug 2026
May 2026
May 2025
26 May · Management
Sep 2024
Aug 2024
13 Aug · Management
Jul 2023
14 Jul · Management
May 2023
30 May · Management
Apr 2023
7 Apr · Management
Dec 2021
30 Dec · Management
Jun 2020
Feb 2020
Aug 2019
May 2019
Feb 2013
7 Feb · Management
Board of Directors of Venus Remedies Limited at its meeting held today i.e. February 07, 2013:- Appointed Mr. S. Sengupta as Nominee director of the Company.
May 2011
3 May · Management
Ms. Neha Kodan, Company Secretary has been appointed as Compliance Officer w.e.f. April 11, 2011 as Ms. Nidhi Singla, Company Secretary has resigned from the Company.
Aug 2009
25 Aug · Management
Board of Directors at its meeting held on August 21, 2009, have accepted resignation of Dr. Anil Gulati as a Non-Executive Director w.e.f. August 17, 2009.
May 2009
6 May · Management
Ms. Nidhi Singla, Company Secretary has been appointed as Compliance Officer w.e.f. May 01, 2009 as Ms. Amarjeet Kaur, Company Secretary has resigned from the Company
May 2008
22 May · Management
Ms. Amarjeet Kaur, Company Secretary has been appointed as Compliance Officer as Ms. Monika Bisht, Company Secretary has resigned from the Company